Characteristics | Total (n = 77) | Period 1 (2016–2018) (n = 52) | Period 2 (2019–2021) (n = 25) | P-value |
---|---|---|---|---|
Age, year (median, IQR) | 1.0 (0.0–6.0) | 0.0 (0.0–3.0) | 2.0 (0.0–9.0) | 0.09 |
Male | 45(58.4) | 31 (59.6) | 11 (40.4) | 0.76 |
Underlying disease | 71 (92.5) | 47 (90.4) | 21 (96.0) | 0.66 |
Heart disease | 26 (33.8) | 17 (32.7) | 9 (36.0) | 0.77 |
Gastrointestinal disease | 19 (24.7) | 11 (21.2) | 8 (32.0) | 0.30 |
Hemato-oncologic disease | 19 (24.7) | 13 (25.0) | 6 (24.0) | 0.92 |
Neurologic disease | 12 (15.6) | 3 (5.8) | 9 (36.0) | < 0.01 |
Renal disease | 7 (9.1) | 4 (7.7) | 3 (12.0) | 0.68 |
Chronic lung disease | 7 (9.1) | 4 (7.7) | 3 (12.0) | 0.68 |
Endocrinologic disease | 7 (9.1) | 4 (7.7) | 3 (12.0) | 0.68 |
Metabolic disease | 5 (6.5) | 3 (5.8) | 2 (8.0) | 0.66 |
Preterm birth (GA < 37weeks) | 14 (18.2) | 11 (21.2) | 3 (12.0) | 0.53 |
Stem cell transplantation a | 7 (9.1) | 5 (9.6) | 2 (8.0) | > 0.99 |
Solid organ transplantation a | 2 (2.6) | 1 (1.9) | 1 (4.0) | 0.55 |
Recent surgery within 1 year | 46 (59.7) | 28 (53.8) | 18 (72.0) | 0.13 |
Immunosuppressive treatment b within 1 month | 19 (25.0) | 12 (23.1) | 7 (29.2) | 0.57 |
Presence of central venous catheter | 65 (84.4) | 42 (80.8) | 23 (92.0) | 0.32 |
ICU stay at the onset of bacteremia | 42 (54.5) | 30 (57.7) | 12 (48.0) | 0.42 |
MRSA colonization before infection | 43 (55.8) | 30 (57.7) | 13 (52.0) | 0.64 |
Place of acquisition | ||||
Hospital onset | ||||
Hospital-acquired infection | 55 (71.4) | 37 (71.2) | 18 (72.0) | 0.94 |
Community onset | ||||
Healthcare-associated infection | 19 (24.7) | 14 (26.9) | 5 (20.0) | 0.51 |
Community-acquired infection | 3 (3.9) | 1 (1.9) | 2 (8.0) | 0.25 |
Primary source of infection | ||||
Central venous catheter infection c | 39 (50.6) | 23 (44.2) | 16 (64.0) | 0.10 |
Skin/soft tissue infection | 8 (10.4) | 6 (11.5) | 2 (8.0) | > 0.99 |
Pneumonia | 6 (7.8) | 4 (7.7) | 2 (8.0) | > 0.99 |
Surgical site infection d | 4 (5.2) | 3 (5.8) | 1 (4.0) | > 0.99 |
Infective endocarditis | 3 (3.9) | 2 (3.8) | 1 (4.0) | > 0.99 |
Bone and joint infection | 2 (2.6) | 0 (0.0) | 2 (8.0) | 0.10 |
Primary bacteremia | 15 (19.5) | 14 (26.9) | 1 (4.0) | 0.03 |
Severe presentation | 13 (16.9) | 7 (13.5) | 6 (24.0) | 0.33 |
Vasopressor use | 8 (10.4) | 6 (11.5) | 2 (8.0) | > 0.99 |
Mechanical ventilation | 7 (9.1) | 3 (5.8) | 4 (16.0) | 0.26 |
Recurrence of MRSA bacteremia | 7 (9.1) | 4 (7.7) | 3 (12.0) | 0.68 |
Duration of bacteremia, days (median, IQR) | 3.0, (1.0–4.0) | 2.0, (1.0–3.0) | 3.0, (1.0–7.0) | 0.30 |
Persistent bacteremia | ||||
3-day | 22 (28.9) | 11 (21.6) | 11 (44.0) | 0.04 |
7-day | 9 (12.0) | 4 (7.8) | 5 (20.8) | 0.13 |
Mortality | ||||
MRSA-related mortality | 3 (3.9) | 3 (5.8) | 0 (0.0) | 0.55 |
30-day all-cause mortality | 8 (10.4) | 5 (9.6) | 3 (12.0) | 0.71 |